title: Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.
abstract: Nicotinic acetylcholine receptors and N-methyl-D-aspartate (NMDA) receptors are known to be down-regulated in the brain of Alzheimer's disease patients. We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor. Because the NMDA receptor is also modulated by Mg2+ and protein kinases, we studied their roles in nefiracetam action on the NMDA receptor by the whole-cell patch-clamp technique and immunoblotting analysis using rat cortical or hippocampal neurons in primary culture. The nefiracetam potentiation of NMDA currents was inhibited by the protein kinase C (PKC) inhibitor chelerythrine, but not by the protein kinase A (PKA) inhibitor N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H89). In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Such an increase in PKCalpha-mediated phosphorylation was prevented by chelerythine. Nefiracetam treatment did not affect the PKA activity. Analysis of the current-voltage relationships revealed that nefiracetam at 10 nM largely eliminated voltage-dependent Mg2+ block and that this action of nefiracetam was sensitive to PKC inhibition. It was concluded that nefiracetam potentiated NMDA currents not by acting as a partial agonist but by interacting with PKC, allosterically enhancing glycine binding, and attenuating voltage-dependent Mg2+ block.
authors.affiliation: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611-3008, USA.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Moriguchi
authors.forename: Norifumi
authors.initials: N
authors.lastname: Shioda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maejima
authors.forename: Xilong
authors.initials: X
authors.lastname: Zhao
authors.forename: William
authors.initials: W
authors.lastname: Marszalec
authors.forename: Jay Z
authors.initials: JZ
authors.lastname: Yeh
authors.forename: Kohji
authors.initials: K
authors.lastname: Fukunaga
authors.forename: Toshio
authors.initials: T
authors.lastname: Narahashi
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004563:Electrochemistry; D005998:Glycine / Q000378:metabolism; D008274:Magnesium / Q000494:pharmacology*; D016202:N-Methylaspartate; D009474:Neurons / Q000166:cytology; D018408:Patch-Clamp Techniques; D010766:Phosphorylation / Q000187:drug effects; D011493:Protein Kinase C / Q000187:drug effects / Q000378:metabolism*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D011760:Pyrrolidinones; D016194:Receptors, N-Methyl-D-Aspartate; C058876:nefiracetam; D016202:N-Methylaspartate; D011493:Protein Kinase C; D008274:Magnesium; D005998:Glycine